Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro (Q35045471)

6 August 2017

title

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro (English)

1 reference

6 August 2017

Tomoyuki Nishimoto

1

1 reference

6 August 2017

Yuichiro Amano

2

1 reference

6 August 2017

Ryuichi Tozawa

3

1 reference

6 August 2017

Eiichiro Ishikawa

4

1 reference

6 August 2017

Yoshimi Imura

5

1 reference

6 August 2017

Hidefumi Yukimasa

6

1 reference

6 August 2017

Yasuo Sugiyama

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

British Journal of Pharmacology

6 August 2017

published in

1 reference

6 August 2017

volume

139

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

911-918

1 reference

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

HMG-CoA reductase inhibitors and myotoxicity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Cholesterol and mortality. 30 years of follow-up from the Framingham study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Plasma triglyceride and coronary heart disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1573926

Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice

25 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJP.0705332

Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol

21 January 2018

1 reference

12 December 2020

Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro

1 reference

12 December 2020

Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels

1 reference

12 December 2020

Lipid lowering effects of pravastatin in common marmosets

1 reference

12 December 2020

The ABCs of cholesterol efflux

1 reference

12 December 2020

Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors

1 reference

12 December 2020

Lipoproteins, cardiovascular disease, and death. The Framingham study

1 reference

12 December 2020

A new genetically obese-hyperglycemic rat (Wistar fatty)

1 reference

12 December 2020

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits

1 reference

12 December 2020

Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat

1 reference

12 December 2020

Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJP.0705332

1 reference

6 August 2017

1 reference

6 August 2017

1 reference